Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 2, 2007

Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 2, 2007

9780521862547
850.50 zł
765.45 zł Save 85.05 zł Tax included
Lowest price within 30 days before promotion: 765.45 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
Product Details
Cambridge University Press
99150
9780521862547
9780521862547

Data sheet

Publication date
2007
Issue number
1
Cover
hard cover
Pages count
284
Dimensions (mm)
170.00 x 244.00
Weight (g)
672
  • 1. Progress in Neurotherapeutics and Neuropsychopharmacology 2007 Jeffrey L. Cummings; 2. A randomized trial comparing unilateral pallidotomy with bilateral subthalamic nucleus stimulation in PD:: perspectives for future implication in clinical practice Rianne A. J. Esselink, Rob M. A. de Bie, Rob J. de Haan, P. Richard Schuurman, Pepijn van den Munckhof and Johannes D. Speelman; 3. The phase II futility clinical trial design Bernard Ravina and Yuko Palesch; 4. Clinical trials in dementia Encarnita Raya-Ampil and Jeffrey L. Cummings; 5. Comparative neuropsychological effects of Lamotrigine and Topiramate in healthy volunteers Kimford J. Meador; 6. Pilot clinical trial of NT-3 in CMT1A patients Zerife Sahenk; 7. New directions in pediatric neuro-oncology practice:: impact of the Childrens Cancer Group Study 9933, a phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma Tobey J. MacDonald; 8. Chemoradiotherapy for primary CNS lymphoma Antonio M. P. Omuro, Joachim Yahalom and Lauren E. Abrey; 9. A double-blind, randomized clinical trial to assess the augmentation with Nimodipine of antidepressant therapy in the treatment of vascular depression F. E. Taragano, P. M. Bagnati and R. F. Allegri; 10. Repetitive transcranial magnetic stimulation:: a novel, noninvasive add-on treatment for medication-resistant depression Tung-Ping Su and Chih-Chia Huang; 11. The NIMH MATRICS initiative:: development of a consensus cognitive battery Robert S. Kern, Michael F. Green and Stephen R. Marder; 12. Review of a randomized controlled trial of adjunctive Bupropion in the treatment of SSRI-induced sexual dysfunction Anna Lembke and Charles DeBattista; 13. Trial-based advances in the treatment of bipolar depression David E. Kemp, Keming Gao, David J. Muzine, Prashant Gajwani and Joseph R. Calabrese; 14. Symptomatic remission in patients with bipolar mania:: results from a double-blind, placebo-controlled trial of Risperidone monotherapy Srihari Gopal, John L. Beyer, David C. Steffens and Michelle L. Kramer; 15. Olanzapine as maintenance therapy in patients with bipolar I disorder Mauricio Tohen and Daniel Yen Lin; 16. Can quality of life be improved in schizophrenia? Results from a pragmatic, randomized controlled trial comparing Olanzapine with first generation antipsychotics Mauricio Silva de Lima, Alan Breier and Jair de Jesus Mari; 17. Combined behavioral and pharmacological treatment of opioid-dependent adolescents:: a randomized, controlled trial Lisa A. Marsch.
Comments (0)

  • Frequently purchased together

    No products available